Aims: To evaluate growth from diagnosis until final height (FH) in 21-hydroxylase deficiency
patients. Methods: A retrospective longitudinal study was performed. Only patients treated …

Aim: To evaluate height, bone growth, areal bone mineral density (aBMD), volumetric bone
mineral density (vBMD) and markers of bone turnover in a group of patients affected by …

Objective: To evaluate the impact of hydrocortisone dosage, age at diagnosis, compliance,
genotype and phenotype on growth and height outcome in 21-hydroxylase-deficient …

Abstract The Endocrine Society Clinical Practice Guidelines on congenital adrenal
hyperplasia (CAH) recommend against using hydrocortisone suspension based on a study …

Objective: To investigate bone mineral density and bone homeostasis in cystic fibrosis (CF)
and to assess changes in a 2-year period. Methods: Thirty-eight patients with clinically …

Congenital adrenal hyperplasia (CAH) is caused by a deficiency in an adrenal enzyme
resulting in alterations in Cortisol and aldosterone production. Bone status is affected by …

Background. We compared the variability of bone age (BA) rating between clinicians and an
automated system in children with congenital adrenal hyperplasia (CAH). Method. A total of …

Congenital adrenal hyperplasia (CAH) is an autosomal recessive group of disorders
characterized by cortisol deficiency and excessive production of adrenal androgens due to …

Patients with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency need
glucocorticoid (GC) therapy, which alters bone mineral metabolism. We analyze clinical and …

It has been shown that changes in IGF-I and IGFBP levels in children with classical
congenital adrenal hyperplasia due to 21-hydroxylase deficiency (CAH) are correlated with …